VBY-825 manufacturers
- VBY-825
-
- $278.00
-
2026-07-27
- CAS:1310340-58-9
- Purity: 99.91%
- Supply Ability: 10g
- VBY-825
-
- $278.00
-
2026-07-27
- CAS:1310340-58-9
- Purity: 99.91%
- Supply Ability: 10g
|
| | VBY-825 Basic information |
| Product Name: | VBY-825 | | Synonyms: | VBY-825;Pentanamide, N-cyclopropyl-3-[[(2R)-3-[(cyclopropylmethyl)sulfonyl]-1-oxo-2-[[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]amino]propyl]amino]-2-oxo-, (3S)-;VBY-825,VBY 825,Cathepsin,Inhibitor,VBY825,inhibit | | CAS: | 1310340-58-9 | | MF: | C23H29F4N3O5S | | MW: | 535.55 | | EINECS: | | | Product Categories: | | | Mol File: | 1310340-58-9.mol |  |
| | VBY-825 Chemical Properties |
| density | 1.39±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 125 mg/mL (233.40 mM);Water : < 0.1 mg/mL (insoluble) | | form | Solid | | pka | 11.83±0.20(Predicted) | | color | White to off-white |
| | VBY-825 Usage And Synthesis |
| Uses | VBY-825 is a novel, reversible cathepsin inhibitor which has high potency against cathepsins B, L, S and V. VBY-825 is also a new and effective anti-tumor drug. | | in vivo | VBY-825 (10 mg/kg, via gavage, once daily, 14 days) reduces pain behaviors in a mouse bone cancer model[2].
VBY-825 inhibits inflammation in mouse models of gout, peritonitis, and arthritis[3]. | Animal Model: | Mouse bone cancer model[2] | | Dosage: | 10 mg/kg; daily; 14 days | | Administration: | i.g. | | Result: | Reduced withdrawal and guarding of spontaneous bone cancer-induced pain. |
| | IC 50 | cathepsin K; cathepsin S |
| | VBY-825 Preparation Products And Raw materials |
|